Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Invivyd, Inc.IVVD · Entity 721 | Director | May 19, 2026 | May 21, 2026 |
| SQZ Biotechnologies CoSQZ · Entity 112267 | Director | June 14, 2023 | June 15, 2023 |
| Wave Life Sciences, Inc.WVE · Entity 4976 | Director · President and CEO | February 05, 2026 | February 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Invivyd, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2036-05-18 | Direct | 32,876 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 32,876 · Balance 32,876 F1: This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.
SQZ Biotechnologies Co
Report date June 14, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2033-06-13 | Direct | 39,875 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 39,875 · Balance 39,875 F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.
Wave Life Sciences, Inc.
Report date February 05, 2026 · Filed February 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 275,520 |
Ending reported balance
After 2026-02-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-05 · Grant · Acquired 165,000 · Balance 286,000 F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030. Row 2 · 2026-02-09 · Sale · Disposed 10,480 · Balance 275,520 F2: On February 9, 2026, the reporting person sold 10,480 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.75 · Expires 2036-02-05 | Direct | 1,000,000 |
Reported balance
After 2026-02-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-05 · Grant · Acquired 1,000,000 · Balance 1,000,000 F3: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.
F2: On February 9, 2026, the reporting person sold 10,480 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
F3: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2019 Filed Mar 19, 2019 22:44 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 5,065 | $45.89 | $232,432.85 |
DisclosureSEC source: 0000899243-19-008404 · doc4.xml · nonDerivative · entry 3 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,209 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2018. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $45.78 to $46.03 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 22:44 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 34,935 | $45.45 | $1,587,795.75 |
DisclosureSEC source: 0000899243-19-008404 · doc4.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,274 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2018. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $44.78 to $45.77 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 22:44 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 50,000 | $2.48 | $124,000.00 |
DisclosureSEC source: 0000899243-19-008404 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2018. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 23:17 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-007112 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,209 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:51 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 119 | $37.47 | $4,458.45 |
DisclosureSEC source: 0000899243-19-004464 · doc4.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,209 F1 · kind: On February 19, 2019, the reporting person sold 7,733 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2019. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $37.4638 to $37.4672 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 00:51 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 7,614 | $36.38 | $276,997.32 |
DisclosureSEC source: 0000899243-19-004464 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,328 F1 · kind: On February 19, 2019, the reporting person sold 7,733 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2019. These sales were made pursuant to a 10b5-1 Trading Plan. Read SEC document |
| May 30, 2018 Filed May 31, 2018 01:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 20,250 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-014497 · doc4.xml · derivative · entry 9 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,778 Underlying: Ordinary Shares · 20,250 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · derivative.exercise_date: The share option represented a right to purchase a total of 422,778 ordinary shares that vest in thirty-six monthly installments beginning on December 12, 2014. Read SEC document |
| May 30, 2018 Filed May 31, 2018 01:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 20,250 | $45.00 | $911,250.00 |
DisclosureSEC source: 0000899243-18-014497 · doc4.xml · nonDerivative · entry 6 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,942 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| May 30, 2018 Filed May 31, 2018 01:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 20,250 | $2.48 | $50,220.00 |
DisclosureSEC source: 0000899243-18-014497 · doc4.xml · nonDerivative · entry 5 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| May 29, 2018 Filed May 31, 2018 01:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 3,145 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-014497 · doc4.xml · derivative · entry 8 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,028 Underlying: Ordinary Shares · 3,145 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · derivative.exercise_date: The share option represented a right to purchase a total of 422,778 ordinary shares that vest in thirty-six monthly installments beginning on December 12, 2014. Read SEC document |
| May 29, 2018 Filed May 31, 2018 01:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 3,145 | $45.00 | $141,525.00 |
DisclosureSEC source: 0000899243-18-014497 · doc4.xml · nonDerivative · entry 4 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,942 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| May 29, 2018 Filed May 31, 2018 01:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 3,145 | $2.48 | $7,799.60 |
DisclosureSEC source: 0000899243-18-014497 · doc4.xml · nonDerivative · entry 3 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| May 25, 2018 Filed May 31, 2018 01:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 8,316 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-014497 · doc4.xml · derivative · entry 7 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,173 Underlying: Ordinary Shares · 8,316 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. F2 · derivative.exercise_date: The share option represented a right to purchase a total of 422,778 ordinary shares that vest in thirty-six monthly installments beginning on December 12, 2014. Read SEC document |
| May 25, 2018 Filed May 31, 2018 01:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 8,316 | $45.00 | $374,220.00 |
DisclosureSEC source: 0000899243-18-014497 · doc4.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,942 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| May 25, 2018 Filed May 31, 2018 01:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 8,316 | $2.48 | $20,623.68 |
DisclosureSEC source: 0000899243-18-014497 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| May 02, 2018 Filed May 5, 2018 00:04 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 18,289 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-18-011575 · doc4.xml · derivative · entry 3 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,489 Underlying: Ordinary Shares · 18,289 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The share option represented a right to purchase a total of 422,778 ordinary shares that vest in thirty-six monthly installments beginning on December 12, 2014. Read SEC document |
| May 02, 2018 Filed May 5, 2018 00:04 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 18,289 | $45.00 | $823,005.00 |
DisclosureSEC source: 0000899243-18-011575 · doc4.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,942 F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| May 02, 2018 Filed May 5, 2018 00:04 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 18,289 | $2.48 | $45,356.72 |
DisclosureSEC source: 0000899243-18-011575 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018. Read SEC document |
| February 16, 2018 Filed Feb 22, 2018 00:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 2,200 | $51.62 | $113,564.00 |
DisclosureSEC source: 0000899243-18-004953 · doc4.xml · nonDerivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,942 F1 · kind: On February 16, 2018, the reporting person sold 2,714 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2018. These sales were made pursuant to a 10b5-1 Trading Plan. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $51.50 to $52.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 16, 2018 Filed Feb 22, 2018 00:18 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 514 | $51.01 | $26,219.14 |
DisclosureSEC source: 0000899243-18-004953 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,142 F1 · kind: On February 16, 2018, the reporting person sold 2,714 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2018. These sales were made pursuant to a 10b5-1 Trading Plan. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $50.40 to $51.15 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 23, 2018 Filed Jan 26, 2018 01:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 109,000 | $0.00 Strike: $40.05 | $0.00 |
DisclosureSEC source: 0000899243-18-002038 · doc4.xml · derivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,000 Underlying: Ordinary Shares · 109,000 shares Expires 2028-01-23 F2 · derivative.exercise_date: The option vests as to 25% of the shares on February 15, 2019 and vests as to an additional 6.25 of the shares quarterly thereafter until February 15, 2022. Read SEC document |
| January 23, 2018 Filed Jan 26, 2018 01:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 54,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002038 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,656 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2019, through February 15, 2022. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 23:14 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 72,500 | $0.00 Strike: $29.05 | $0.00 |
DisclosureSEC source: 0000899243-17-002145 · doc4.xml · derivative · entry 2 BOLNO PAUL · CIK 0001657710 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Ordinary Shares · 72,500 shares Expires 2027-01-25 F2 · derivative.exercise_date: The option vests as to 25% of the shares on February 15, 2018 and vests as to an additional 2.0833% of the shares monthly thereafter until February 15, 2021. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 23:14 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 36,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-002145 · doc4.xml · nonDerivative · entry 1 BOLNO PAUL · CIK 0001657710 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,156 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2018, through February 15, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.